BIKY Pharma
Pharmaceutical laboratory focused on vaporization-based drug delivery. Develops inhalable liquid formulations, an electronic vaporization delivery system, and candidate therapeutics for smoking cessation, pain management (cannabis-derived molecules), and respiratory diseases. Activities include preclinical development, planned Phase I/II clinical studies, device conformity with European medical device regulations, and collaborations with clinical and academic partners.
Industries
Nr. of Employees
small (1-50)
BIKY Pharma
6 allée Jean Orcel, Fontanil Cornillon, FRANCE
Products
Electronic vaporization medical device (battery-powered system)
An electronic drug delivery device designed for controlled vaporization of prefilled, dosed cartridges with aspiration-triggered activation and patient auto-titration functionality. Intended for therapeutic administration via inhalation.
NICØDIØL (candidate inhaled therapy for smoking cessation)
A candidate inhaled medicine combining nicotine and cannabidiol delivered via liquid vaporization and a tiered substitution protocol designed to support smoking cessation.
e-NADØL (candidate inhalable analgesic formulation)
A THC-dominant liquid vaporisable formulation intended for rapid, microdosed management of pain via pulmonary administration, developed to minimize systemic side effects and avoid excessive psychoactive dosing.
Respiratory bronchodilator program (BPCO/asthma candidate)
Development program for inhaled bronchodilators (e.g., salbutamol, terbutaline) administered via vaporization to provide immediate bronchodilation with simplified user coordination and without propellant gases.
Electronic vaporization medical device (battery-powered system)
An electronic drug delivery device designed for controlled vaporization of prefilled, dosed cartridges with aspiration-triggered activation and patient auto-titration functionality. Intended for therapeutic administration via inhalation.
NICØDIØL (candidate inhaled therapy for smoking cessation)
A candidate inhaled medicine combining nicotine and cannabidiol delivered via liquid vaporization and a tiered substitution protocol designed to support smoking cessation.
e-NADØL (candidate inhalable analgesic formulation)
A THC-dominant liquid vaporisable formulation intended for rapid, microdosed management of pain via pulmonary administration, developed to minimize systemic side effects and avoid excessive psychoactive dosing.
Respiratory bronchodilator program (BPCO/asthma candidate)
Development program for inhaled bronchodilators (e.g., salbutamol, terbutaline) administered via vaporization to provide immediate bronchodilation with simplified user coordination and without propellant gases.
Services
Partnerships with clinical centers and academic labs to design and execute preclinical studies and early-phase clinical trials for inhaled therapeutics.
Partnerships with clinical centers and academic labs to design and execute preclinical studies and early-phase clinical trials for inhaled therapeutics.
Expertise Areas
- Inhalation drug delivery
- Formulation development for vaporization
- Medical device development for drug delivery
- Early-phase clinical development
Key Technologies
- Vaporization-based drug delivery
- Electronic drug delivery systems (SEDEM)
- Inhalable liquid formulation development
- Prefilled sealed cartridge technology
News & Updates
In vitro evaluation of THC inhalation performance using regulated and commercial vaping technologies
In vitro study comparing inhalation performance metrics (MMAD, FPF, transfer efficiency) between a regulated electronic delivery system and a commercial vape pen for THC administration; reports submicron particle sizes and comparable transfer efficiencies with more consistent respirable dose from the regulated system.
Press coverage describing the development of a new electronic nicotine substitution approach by the company.
Obtained CE marking for the vaporization medical device battery in early 2025 under the European medical device regulation 2017/745.
In vitro evaluation of THC inhalation performance using regulated and commercial vaping technologies
In vitro study comparing inhalation performance metrics (MMAD, FPF, transfer efficiency) between a regulated electronic delivery system and a commercial vape pen for THC administration; reports submicron particle sizes and comparable transfer efficiencies with more consistent respirable dose from the regulated system.
Press coverage describing the development of a new electronic nicotine substitution approach by the company.
Obtained CE marking for the vaporization medical device battery in early 2025 under the European medical device regulation 2017/745.